Register for our free email digests:
Division of AstraZeneca PLC
Latest From American Cyanamid Co.
Watson’s merger with Actavis will create the world’s third-largest generic drug company, to be known as Actavis, with significant ex-U.S. market share, especially in the U.K., Nordic countries and Russia.
With the Actavis deal finalized, Watson achieves its long-sought goal of becoming a major international player in generics, and announces a new global management team to undertake the critical component: execution.
The agency issued a list of 364 ANDAs that will be deemed withdrawn unless the sponsor tells FDA it wishes to pursue them; it is a first step in clearing the backlog before generic drug user fees are enacted.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- AstraZeneca PLC
- Senior Management
Michael Richman, Pres. & CEO
Sol Langerman, PhD, SVP, CSO
Gary Fanger, PhD, SVP, COO
- Contact Info
Phone: (301) 309-9800
45 West Watkins Mill Rd.
Gaithersburg, MD 20878
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.